I-Corps: Photodynamic Cancer Therapy Innovation

I-Corps：光动力癌症治疗创新

• 批准号: 1542256
• 负责人: Matthew Gdovin
• 金额: $ 5万
• 依托单位: University of Texas at San Antonio
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-06-01 至 2016-05-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=1542256&HistoricalAwards=false
• 关键词: Corps; Photodynamic; Cancer; Therapy; Innovation

Triple Negative Breast Cancer (TNBC) represents one of the most aggressive, deadly forms of breast cancer, and because this cancer lacks estrogen, progesterone, and Human Epidermal Growth Factor (HER-2) receptors, many existing pharmacological treatments have a limited effect on patient survival. The proposed innovation aims to address the lack of targeted therapies for effective treatment of TNBC, as the lack of an efficient targeted approach represents a significant barrier for patients diagnosed with TNBC. Because TNBC responds so poorly to chemotherapy, a mastectomy is often performed to increase overall survival. The proposed innovation may eliminate the need for mastectomy. Potential customers include physicians, health care administrators, and patients. In addition to oncologists that would prescribe our treatment, customers would also include people who influence the decision to use the proposed treatment. These customers would include health care providers.Induction of intracellular acidosis via photo uncaging of protons has until not been pursued as a technique for inflicting damage to cells. Releasing significant concentrations of hydrogen ions causes variable disruption to biological systems, and can be used to cause apoptotic cell death in a focal region such as within a tumor. This fundamental alteration to cells intracellular pH is almost impossible to garner a resistance toward, has been shown to be highly effective in causing significant cancer cell death in vitro and in vivo, has an acutely focal effect providing limitless potential for specific cell targeting using a recently developed pH-inducing photodynamic nanoparticle, and is an abundant and relatively inexpensive chemical compound. The commercial viability of this intellectual property has tremendous potential, as the mechanisms of action employed in causing significant death of TNBC cells in vitro and in vivo is not cancer specific. If developed and entered into the market, the proposed intracellular acidosis anti-cancer technique has the potential to rival or surpass current chemotherapeutic, radiation, or surgical methods of cancer treatment. This I-Corps team intends to establish the current unmet needs of all principals in the TNBC treatment space, specifically oncologists, hospital administrators, pharmaceutical companies, patients, and FDA regulators. The team will also identify needs for pharmacokinetic and pharmacodynamics studies. At the end of the project this team will draft a business plan which will include a mission statement, objectives, keys to success, products and services, management plan, market analysis to include customers, pricing, competition, and delivery, and measurable milestones of progress.

三阴性乳腺癌（TNBC）代表了乳腺癌的最具侵略性，最致命的形式之一，因为这种癌症缺乏雌激素，孕酮和人表皮生长因子（HER-2）受体，许多现有的药物治疗对患者生存的影响有限。提出的创新旨在解决缺乏有效治疗TNBC的靶向疗法的问题，因为缺乏有效的靶向方法是诊断患有TNBC的患者的重大障碍。由于TNBC对化疗的反应很差，因此通常进行乳房切除术以提高总体生存率。拟议的创新可能消除乳房切除术的需要。潜在的客户包括医生、卫生保健管理人员和患者。除了会开我们治疗处方的肿瘤学家外，客户还包括影响使用拟议治疗决定的人。这些客户将包括医疗保健提供者。通过质子的光释放诱导细胞内酸中毒直到现在还没有被作为一种对细胞造成损害的技术来追求。释放显著浓度的氢离子对生物系统造成可变的破坏，并且可用于在病灶区域（例如肿瘤内）引起凋亡性细胞死亡。这种对细胞内pH的根本改变几乎不可能获得抵抗，已经显示在体外和体内引起显著的癌细胞死亡方面非常有效，具有急性聚焦效应，为使用最近开发的pH诱导光动力纳米颗粒的特异性细胞靶向提供无限的潜力，并且是丰富且相对便宜的化合物。该知识产权的商业可行性具有巨大的潜力，因为在体外和体内引起TNBC细胞显著死亡的作用机制不是癌症特异性的。如果开发并进入市场，所提出的细胞内酸中毒抗癌技术有可能竞争或超过目前的化疗，放疗或手术治疗癌症的方法。 该I-Corps团队旨在确定TNBC治疗领域所有负责人当前未满足的需求，特别是肿瘤学家，医院管理人员，制药公司，患者和FDA监管机构。该小组还将确定药代动力学和药效学研究的需求。在项目结束时，该团队将起草一份业务计划，其中包括使命声明、目标、成功关键、产品和服务、管理计划、市场分析（包括客户、定价、竞争和交付）以及可衡量的进展里程碑。